scholarly article | Q13442814 |
P50 | author | Ling Yang | Q89474643 |
P2093 | author name string | Yan Chen | |
Ling Yang | |||
Zhenzhen Wang | |||
Gen-Sheng Feng | |||
Yi Pan | |||
Yixuan Zhang | |||
Zhenghu Li | |||
Xiangbo Ruan | |||
P2860 | cites work | Identification and importance of brown adipose tissue in adult humans | Q24632425 |
AMPK and PPARdelta agonists are exercise mimetics | Q24652674 | ||
Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1 | Q28131760 | ||
Obesity and the risk of heart failure | Q28216583 | ||
Transcriptional control of brown fat determination by PRDM16 | Q28593210 | ||
Cold-activated brown adipose tissue in healthy men | Q29547382 | ||
Brown adipose tissue: function and physiological significance | Q29547448 | ||
Functional brown adipose tissue in healthy adults | Q29547687 | ||
Mechanisms linking obesity to insulin resistance and type 2 diabetes | Q29614887 | ||
Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. | Q31887210 | ||
High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation | Q33782094 | ||
Insulin resistance and cardiovascular disease | Q34011027 | ||
The obesity epidemic, metabolic syndrome and future prevention strategies | Q34323455 | ||
New methods for calculating metabolic rate with special reference to protein metabolism | Q34351677 | ||
Mechanisms linking obesity with cardiovascular disease | Q34590832 | ||
Atheroprotective effects of high-density lipoproteins | Q34987979 | ||
Metabolic syndrome: a clinical and molecular perspective | Q36014668 | ||
HDL as a target in the treatment of atherosclerotic cardiovascular disease | Q36058450 | ||
Apolipoprotein A-I mimetic peptides | Q36098714 | ||
Respiration uncoupling and metabolism in the control of energy expenditure | Q36118740 | ||
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients | Q36662681 | ||
L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice | Q36745004 | ||
Effect of obesity on high-density lipoprotein metabolism | Q37058273 | ||
Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses | Q37370951 | ||
Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism | Q40105268 | ||
Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. | Q41275648 | ||
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. | Q41759689 | ||
Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol | Q43862770 | ||
The disease burden associated with overweight and obesity | Q44817527 | ||
Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit | Q45032346 | ||
Synthetic peptide analogs of apolipoproteins | Q45187676 | ||
D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet | Q46675074 | ||
Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis | Q46705057 | ||
An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma | Q46868439 | ||
Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity | Q47902556 | ||
Obesity and lipoprotein cholesterol in the Framingham offspring study. | Q52755652 | ||
Long-Term Treatment with the Apolipoprotein A1 Mimetic Peptide Increases Antioxidants and Vascular Repair in Type I Diabetic Rats | Q60684945 | ||
Beta-adrenergic, cAMP-mediated stimulation of proliferation of brown fat cells in primary culture. Mediation via beta 1 but not via beta 3 adrenoceptors | Q67879410 | ||
Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease | Q70442465 | ||
Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women | Q77647860 | ||
Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice | Q80317215 | ||
Apolipoprotein A-I mimetic peptides | Q82957586 | ||
P433 | issue | 4 | |
P921 | main subject | obesity | Q12174 |
P304 | page(s) | 763-772 | |
P577 | publication date | 2011-04-01 | |
P1433 | published in | Journal of Cellular and Molecular Medicine | Q1524063 |
P1476 | title | Apolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and up-regulation of UCP1 in brown fat. | |
P478 | volume | 15 |
Q35926657 | ApoA-1 mimetic restores adiponectin expression and insulin sensitivity independent of changes in body weight in female obese mice |
Q43160205 | ApoA-I Milano stimulates lipolysis in adipose cells independently of cAMP/PKA activation |
Q61800652 | Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle |
Q35172781 | Apolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice |
Q92422017 | Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research |
Q36593117 | Brown adipose tissue and its modulation by a mitochondria-targeted peptide in rat burn injury-induced hypermetabolism |
Q42252464 | CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice |
Q27000421 | Cardioprotective functions of HDLs |
Q37394438 | Changes in triglycerides and high-density lipoprotein cholesterol may precede peripheral insulin resistance, with 2-h insulin partially mediating this unidirectional relationship: a prospective cohort study |
Q38313076 | Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. |
Q92949881 | Effects of obesity on cholesterol metabolism and its implications for healthy ageing |
Q37590250 | HDL and cholesterol: life after the divorce? |
Q38293471 | HDLs, diabetes, and metabolic syndrome |
Q34565254 | High density lipoprotein: it's not just about lipid transport anymore |
Q37603213 | High density lipoproteins improve insulin sensitivity in high-fat diet-fed mice by suppressing hepatic inflammation |
Q37642841 | High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice |
Q64277669 | Human ApoA-I Overexpression Enhances Macrophage-Specific Reverse Cholesterol Transport but Fails to Prevent Inherited Diabesity in Mice |
Q48726745 | In vivo PET imaging with [(18)F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes. |
Q37331224 | Influence of apolipoproteins on the association between lipids and insulin sensitivity: a cross-sectional analysis of the RISC Study |
Q92016771 | Interaction between adipocytes and high-density lipoprotein:new insights into the mechanism of obesity-induced dyslipidemia and atherosclerosis |
Q34299607 | Low high-density lipoprotein cholesterol level is a significant risk factor for development of type 2 diabetes: Data from the Hawaii-Los Angeles-Hiroshima study |
Q37614469 | Modulation of adipose tissue lipolysis and body weight by high-density lipoproteins in mice |
Q35267682 | New kids on the block: the emerging role of apolipoproteins in the pathogenesis and treatment of asthma |
Q36406480 | Novel biological functions of high-density lipoprotein cholesterol |
Q33755805 | Overexpression of apolipoprotein A-I alleviates endoplasmic reticulum stress in hepatocytes |
Q64227581 | Peptides and Peptidomimetics as Potential Antiobesity Agents: Overview of Current Status |
Q26859684 | Regulation of adipocyte autophagy--the potential anti-obesity mechanism of high density lipoprotein and ApolipoproteinA-I |
Q37076473 | Regulation of signal transduction by HDL. |
Q27000047 | Research advances at the Institute for Nutritional Sciences at Shanghai, China |
Q38553529 | Targeting inflammation in metabolic syndrome. |
Q37978209 | The emerging role of HDL in glucose metabolism |
Q28069220 | The unsolved mystery of apoA-I recycling in adipocyte |
Q86542655 | [Concept of reconstructive body shaping in obesity. Evidence-based therapy algorithm] |